Europe is actively working to improve the clinical research environment, with particular emphasis on supporting biotechnology innovation and adapting to evolving scientific and societal needs. As new legislative initiatives such as the Biotech Act take shape, there is a growing focus on creating a more responsive and inclusive framework for clinical trials. This session brings together patients, regulators, and clinical trials’ sponsors to explore how the European Medicines Regulatory Network (EMRN) addresses these priorities. A central theme will be the importance of transparency and accountability, underscored by the recent introduction of EU-wide Key Performance Indicators (KPIs). The discussion will expand on the upcoming Clinical Research Investment Plan, to be launched under the European Commission’s flagship Life Science Strategy, as well as FDA’s efforts to support innovation in clinical research in the US. Participants will gain a clearer understanding of how clinical trial conduct is evolving in the EU, the challenges that remain, and how collective action can support a more effective and innovation-ready research ecosystem.